Gau J P, Young J H, Lin T H, Yang Y S
Department of Internal Medicine, Taichung Veterans General Hospital, Taiwan, ROC.
Zhonghua Yi Xue Za Zhi (Taipei). 2000 Mar;63(3):175-81.
Rapid and accurate diagnosis of acute promyelocytic leukemia (APL) is essential for management of the disease, as all-trans retinoic acid (ATRA) therapy only induces complete remission in patients whose leukemic cells harbor a t(15;17) translocation, resulting in promyelocytic-retinoic acid receptor alpha (PML-RAR alpha) fusion transcripts. Moreover, a positive reverse transcriptase-polymerase chain reaction (RT-PCR) of PML-RAR alpha is reported to be a sensitive predictor of relapse in APL. This prompted us to use RT-PCR for rapid diagnosis and monitoring of minimal residual disease in APL patients.
A nested RT-PCR technique was applied to detect the unique PML-RAR alpha fusion transcript in 13 APL patients. The test was applied to help clarify the diagnosis and monitor minimal residual disease after treatment.
All 13 APL patients had a positive test result: five patients with the S-form, seven patients with the L-form and one patient with the V-form of mRNA fusion transcripts. Minimal residual disease was prospectively monitored using this technique in six patients. Although in clinical remission, all four patients treated with ATRA alone were persistently PCR positive. Of the six patients receiving various forms of consolidation chemotherapy, one was persistently PCR positive while in remission and relapsed four months after the positive PCR test. Five patients were PCR negative. One of the five negative patients relapsed six months after a negative PCR test. The other four patients remained in remission, with a follow-up period of 25 to 46 months after the negative test. PCR was performed in two patients who had been in continuous remission for 3.5 and seven years, respectively. They both had negative PCR tests.
Nested RT-PCR is valuable for confirming the diagnosis of APL and in monitoring minimal residual disease. However, we found that negative test cannot absolutely exclude the possibility of future relapse.
急性早幼粒细胞白血病(APL)的快速准确诊断对于该疾病的治疗至关重要,因为全反式维甲酸(ATRA)疗法仅能使白血病细胞具有t(15;17)易位,从而产生早幼粒细胞-维甲酸受体α(PML-RARα)融合转录本的患者实现完全缓解。此外,据报道PML-RARα的逆转录酶-聚合酶链反应(RT-PCR)阳性是APL复发的敏感预测指标。这促使我们使用RT-PCR对APL患者进行快速诊断和微小残留病监测。
应用巢式RT-PCR技术检测13例APL患者中独特的PML-RARα融合转录本。该检测用于辅助明确诊断并监测治疗后的微小残留病。
13例APL患者检测结果均为阳性:5例为mRNA融合转录本的S型,7例为L型,1例为V型。使用该技术对6例患者进行了前瞻性微小残留病监测。尽管处于临床缓解期,但仅接受ATRA治疗的4例患者PCR持续阳性。在接受各种形式巩固化疗的6例患者中,1例在缓解期PCR持续阳性,并在PCR检测阳性4个月后复发。5例患者PCR阴性。5例阴性患者中有1例在PCR检测阴性6个月后复发。其他4例患者仍处于缓解期,阴性检测后随访期为25至46个月。对分别持续缓解3.5年和7年的2例患者进行了PCR检测。他们的PCR检测均为阴性。
巢式RT-PCR对于确诊APL和监测微小残留病具有重要价值。然而,我们发现阴性检测不能绝对排除未来复发的可能性。